[Thanks to Swaraj Barooah sharing an in-progress draft from a project he is working on examining cancer litigation in India. The questions in there led me to write this post.] Can a court say a com…

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new indication allows treatment for adult patients with a…

Apply for CDSCO Registration in India for medical devices, drugs & cosmetics. File via SUGAM portal with DCGI experts. Fast approval, full compliance. Free consult!

YouTube video by The Health Master

4일 온라인으로 2026 데마시아컵 글로벌 인비테이셔널(DCGI) 2라운드 승자전 경기가 진행됐다. 그 결과, BNK 피어엑스는 LPL의 LGD를 상대로 2:1로 승리, kt 롤스터는 브라질 CBLOL의 레드 캐니즈를 2:0으로 격파했고, 한진 브리온은 LPL WE에게 1:2로 패배했다. BFX와 LGD의 1세트, 양 팀의 정글러들이 활약하며 바텀 위주의

3일 개막한 2026 데마시아컵 글로벌 인비테이셔널에서 kt 롤스터, BNK 피어엑스, 한진 브리온이 1라운드를 승리하며 2라운드 승자조에 진출했다. 4일 오후 4시부터 열리는 2라운드 승자조에서 kt 롤스터는 레드 카니즈 칼룽가, 한진 브리온은 팀 WE, BNK 피어엑스는 LGD 게이밍과 대결한다. 승리 팀은 녹아웃 스테이지에 직행하며 패자조 경기는 5일...

The Central Drugs Standard Control Organisation (CDSCO) has formed an expert committee on artificial intelligence (AI), Drugs Controller General of India (DCGI) Rajeev Singh Raghuvanshi said on September 18. CDSCO has not published an order constituting the committee, a member list, terms of reference or a timeline. “Regulation of AI in healthcare is a subject that is being discussed by all agencies globally,” Raghuvanshi said at the 8th Confederation of Indian Industry (CII) Pharma and Lifesciences Summit in New Delhi, according to…

YouTube video by Monroe County Legislature

YouTube video by 【ゲーム・バズネタ】いんたーねっと反応集

Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. This quarter continued to display strong performance with healthy growth in Adj EBITDA and Adj PAT.In Q1 FY26, Akums reported total income of Rs. 1,051 crore, with healthy Adj EBITDA of Rs. 156 crore reflecting a robust 19.1% year-on-year (YoY) growth. The margins improved to 14.8% from 12.7% last year a 208 bps improvement.During this quarter, the company achieved a key milestone of reaching 1,000 Drug Controller General of India (DCGI) approvals, with 27 fresh approvals in this quarter. The DCGI approvals assist the company in enhancing its product mix, building a differentiated and research-driven portfolio. Additionally, the company also received a patent for its extended-release combination formulation of Doxylamine and Pyridoxine developed using the company's tablet in tablet technology.As part of Akums' strategic vision to establish itself as a leading global CDMO, the company received its first EU dossier approval for Rivaroxaban. It also filed its first dossier of Dapagliflozin combination in Switzerland. Both of these new products hold significant market potential. The commercialization of the EU contract also continues to be on track and the company will commence commercial supplies from April 2027.Akums received 100 mn Euros as part consideration for the EU contract in Q1 this year, consequently the company is at a cash surplus of Rs. 1,518 cr. The strong liquidity position provides a robust foundation for Akums to strategically scale up its business operations through both organic growth initiatives and inorganic opportunities.Segmental Performance Overview Akums' flagship business, CDMO, contributed ~79% to the group turnover with an EBITDA of 14.7% in Q1 FY 26. The company's domestic branded formulation business segment reported ~3% YoY growth while international branded formulation business grew by ~2% YoY. Trade generics and API segment continue to be in operational loss this quarter, though, through the management efforts, the losses are gradually reducing.Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, "This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor."Mr. Sandeep Jain, Managing Director, added, "We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead."Extract of Consolidated financial resultsParticulars (Rs Cr)Q1 FY 26Q4 FY 25Q1 FY 25 Revenue 1,024 1,056 1,019 Other income 27 18 7Total income1,0511,0731,026 Cost of goods sold 582 639 596 Employee Cost 176 184 176 Other Expenses 137 139 123Adj EBITDA156111131Adj EBITDA Margin14.8%10.4%12.7%Adj PAT654457Adj PAT Margin6.2%4.1%5.6%Definitions Adjusted EBITDA has been calculated as the sum of profit/ (loss) for the quarter, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, and exceptional items.Adjusted PAT is calculated as the profit for the quarter plus fair value changes to financial instruments less tax deferred tax created on brought forward losses.CDMO: Contract Development and Manufacturing OperationsAPI: Active Pharmaceutical Ingredients Akums Reports Q1 FY26 with 19% YoY Adj EBITDA Growth; Achieves 1,000 DCGI Approvals